Mead Johnson Nutrition Company (NYSE:MJN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.64 by 11 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 6 Brokerage Firms have advised hold. A sell rating was given by 2 analyst.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Citigroup maintains its outlook on Mead Johnson Nutrition Company (NYSE:MJN). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $85 per share to $100 per share. The rating by the firm was issued on April 18, 2016.
Mead Johnson Nutrition Company (NYSE:MJN): The stock price is expected to reach $ 80.67 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $89 while the lower estimate is at $70. The standard deviation of the price stands at $6.89.
Mead Johnson Nutrition Company (NYSE:MJN) rose 1.2% or 1.05 points on Tuesday and made its way into the gainers of the day. After trading began at $87.4 the stock was seen hitting $88.6 as a peak level and $87.4 as the lowest level. The stock ended up at $88.41. The daily volume was measured at 1,756,471 shares. The 52-week high of the share price is $93.07 and the 52-week low is $65.53. The company has a market cap of $16,503 million.
Shares of Mead Johnson Nutrition Company rose by 7.56% in the last five trading days and 8.08% for the last 4 weeks. Mead Johnson Nutrition Company is up 9.67% in the last 3-month period. Year-to-Date the stock performance stands at 13.15%.
Mead Johnson Nutrition Company (Mead Johnson) is a global pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, childrens nutrition and other nutritional products. Its product portfolio includes routine and specialty infant formulas, childrens milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders. The Company operates through three segments: Asia, Latin America and North America/Europe. The Companys Enfa family of brands, including Enfamil infant formula, is a brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants, children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers, healthcare professionals and retailers in more than 50 countries in Asia, North America, Latin America and Europe.